About this Research Topic
Myeloid cells play a pivotal role within the immunosuppressive tumor microenvironment, influencing the progression and treatment resistance of various cancers. The accumulation of tumor-modified myeloid cells, such as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs), is closely associated with poor clinical outcomes and resistance to a range of treatments, including chemotherapy, immune checkpoint inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapy. Although large-scale clinical trials of myeloid cell modulators have seen limited success, significant advancements have been made in both preclinical and clinical settings. These advancements encompass targeting immunometabolism pathways, epigenetic signaling, and chemokine receptors, as well as the immunosuppressive machinery molecules of suppressive myeloid cells. Additionally, strategies promoting myeloid cell differentiation or depletion have shown promise, offering new avenues for therapeutic intervention and improving the efficacy of existing cancer treatments.
The goal of this Research Topic is to provide a forum to advance research on the context-specific roles of different myeloid cell populations in disease progression and their influence on therapy response. Additionally, we aim to determine the most effective treatment regimens and combination partners according to tumor types and patient subsets.
We welcome the latest research progress in related fields, both preclinical and clinical, and invite the submission of review or research papers. Manuscripts may explore, but are not limited to, the following areas:
1. Targeting therapy for tumor-modified myeloid cells, such as MDSCs, TAMs, and TANs.
2. Combined targeting of different myeloid cells with lymphocyte-based immunotherapies, such as immune checkpoint inhibitors, CAR-T, and CAR-NK.
3. Mechanisms by which myeloid cells act as the dominant drivers of therapy resistance.
4. New technologies for the targeted regulation of myeloid cells.
5. Profiling tumors for patient selection based on specific myeloid cells in different human cancers.
The goal of this Research Topic is to provide a forum to advance research on the context-specific roles of different myeloid cell populations in disease progression and their influence on therapy response. Additionally, we aim to determine the most effective treatment regimens and combination partners according to tumor types and patient subsets.
We welcome the latest research progress in related fields, both preclinical and clinical, and invite the submission of review or research papers. Manuscripts may explore, but are not limited to, the following areas:
1. Targeting therapy for tumor-modified myeloid cells, such as MDSCs, TAMs, and TANs.
2. Combined targeting of different myeloid cells with lymphocyte-based immunotherapies, such as immune checkpoint inhibitors, CAR-T, and CAR-NK.
3. Mechanisms by which myeloid cells act as the dominant drivers of therapy resistance.
4. New technologies for the targeted regulation of myeloid cells.
5. Profiling tumors for patient selection based on specific myeloid cells in different human cancers.
Keywords: myeloid cells, tumor microenvironment, immunotherapy resistance, cancer treatment, myeloid-derived suppressor cells (MDSCs)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
